SCHEMBL7809671

SCHEMBL7809671

OC(c1ccccc1)c1ccccc1C(O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.63
MAPT P10636 1/20 0.63
CYP2C9 P11712 1/20 0.63
KMT2A Q03164 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.48
LMNA P02545 3/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
TSHR P16473 1/20 0.44
GAA P10253 1/20 0.44
DRD2 P14416 1/20 0.43
DRD1 P21728 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2C P18825 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9193862 0.87 MEN1 (0.52) MEN1MAPTCYP2C9KMT2ASMN1; SMN2
SCHEMBL984999 0.85 MAPT (0.50) MEN1MAPTCYP2C9KMT2ASMN1; SMN2
SCHEMBL275909 0.85 CA1 (0.50) MEN1MAPTCYP2C9KMT2A
SCHEMBL6578256 0.85 MEN1 (0.50) MEN1MAPTCYP2C9KMT2ASMN1; SMN2
SCHEMBL29405346 0.85 MAPT (0.50) MEN1MAPTCYP2C9KMT2ASMN1; SMN2
SCHEMBL9575839 0.85 MEN1 (0.50) MEN1MAPTCYP2C9KMT2ASMN1; SMN2
Diphenylmethanol SCHEMBL10868602 0.84 SMN1; SMN2 (0.61) SMN1; SMN2LMNAMAPK1L3MBTL1TSHR
Diphenylmethanol SCHEMBL41571 0.84 SMN1; SMN2 (0.61) SMN1; SMN2LMNAMAPK1L3MBTL1TSHR
Diphenylmethanol SCHEMBL11564700 0.84 SMN1; SMN2 (0.61) SMN1; SMN2LMNAMAPK1L3MBTL1TSHR
Diphenylmethanol SCHEMBL6434457 0.84 SMN1; SMN2 (0.61) SMN1; SMN2LMNAMAPK1L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-7196568-A None JP disclosed
US-20230143961-A1 NOVEL ANTHRACENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME SFC CO., LTD. (KR) 2023-05-11 US disclosed
US-6316170-B2 COATING, EXPOSURE, DEVELOPMENT AND HEAT TREATMENT KABUSHIKI KAISHA TOSHIBA (JP) 2001-11-13 US disclosed
US-20010006767-A1 Developing solution and method of forming polyimide pattern by using the developing solution YOSHIAKI KAWAMONZEN 2001-07-05 US disclosed
JP-H07196568-A BIS(HYDROXYBENZYL)BENZENE COMPOUND, ITS EPOXY RESIN AND THEIR PRODUCTION MITSUI TOATSU CHEM INC 1995-08-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143961-A1 NOVEL ANTHRACENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY2, TRPA1, ANXA1 MEN1 1218/4885MAPT 1371/4885CYP2C9 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.